ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany
PA8
PALISADE BIO, INC. Logo
Developing oral precision therapies for inflammatory and fibrotic intestinal diseases like colitis.
United States of America
PALI

Talk to a Data Expert

Have a question? We'll get back to you promptly.